The LXR pan agonist DMHCA reduces fibrosis in several non-tumorigenic disease models [23, 38, 44, 45], and therefore we evaluated its efficacy in our conditional NeuT/ATTAC+AP mammary fibrosis model expressing a constitutively active ErbB2 gene and LXRβ/NR1H2 as the major isoform [27]. Here, NR1H2 is linked to alkaline phosphatase measurement.